Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

BACKGROUND Hallucinations and delusions are frequent in patients with Parkinson disease (PD) and may have severe clinical consequences for those patients and their caregivers. However, the prevalence and clinical features of these symptoms have not been studied in a representative sample. OBJECTIVE To study the prevalence and clinical correlates of psychosis in a population-based sample of patients with PD. METHOD Total ascertainment of patients with PD in a defined geographical area in Norway was attempted through a detailed community study. Clinical evaluation consisted of a neurologic examination and assessments of depression and cognition. Psychosis was assessed with the thought disorder subscale of the Unified Parkinson's Disease Rating Scale. RESULTS A total of 245 patients with PD were identified, 235 (95.9%) of whom participated in this study. Twenty-three patients (9.8%) had hallucinations with insight retained, and another 14 patients (6.0%) had more severe hallucinations or delusions. Psychotic symptoms were associated with age, stage and diagnostic subgroup of PD, severity of depression, and cognitive impairment. Type, duration, and dose of antiparkinson drug therapy did not differ between those patients with PD who had or did not have psychosis. In a polychotomous logistic regression analysis, severity of depression, cognitive impairment, and impairment of activities of daily living were the only significant concomitants of psychosis. CONCLUSIONS Hallucinations and delusions are common in patients with PD. More advanced and widespread brain changes seem to increase the risk for developing psychosis in patients with PD receiving levodopa therapy.

[1]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[2]  Wilfrid Joseph Dixon,et al.  Bmdp Statistical Software Manual: To Accompany the 1988 Software Release , 1988 .

[3]  S. Fahn,et al.  Parkinsonian features of eight pathologically diagnosed cases of diffuse lewy body disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[4]  J. Cummings,et al.  Neuropsychiatric aspects of Alzheimer's disease , 1996, Neurology.

[5]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[6]  S. Factor,et al.  Parkinson's disease: drug-induced psychiatric states. , 1995, Advances in neurology.

[7]  T. Riise,et al.  The epidemiology of Parkinson's disease in the county of Rogaland, Norway , 1995, Movement disorders : official journal of the Movement Disorder Society.

[8]  G. Bråne,et al.  A new rating scale for dementia syndromes. , 1982, Archives of gerontology and geriatrics.

[9]  D. Kömpf,et al.  A study of visual hallucinations in patients with Parkinson’s disease , 1997, Journal of Neurology.

[10]  J. Cummings,et al.  Frequency of dementia in Parkinson disease. , 1996, Archives of neurology.

[11]  P. Kelly,et al.  Dementia with Lewy Bodies: What is the neuropathological basis of dementia associated with Lewy bodies? , 1996 .

[12]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[13]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[14]  E. Perry,et al.  Cerebral Cholinergic Activity Is Related to the Incidence of Visual Hallucinations in Senile Dementia of Lewy Body Type , 1990 .

[15]  R. Mayeux,et al.  Altered serotonin metabolism in depressed patients with Parkinson's disease , 1984, Neurology.

[16]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[17]  C. Goetz,et al.  Pharmacology of hallucinations induced by long-term drug therapy. , 1982, The American journal of psychiatry.

[18]  E. Wolters,et al.  Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease , 1996, Neurology.

[19]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[20]  E. Dupont,et al.  Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence , 1994, Acta neurologica Scandinavica.

[21]  J. Cummings Behavioral Complications of Drug Treatment of Parkinson's Disease , 1991, Journal of the American Geriatrics Society.

[22]  M. Akil,et al.  Clozapine as a treatment for psychosis in Parkinson's disease: a review. , 1996, The Journal of neuropsychiatry and clinical neurosciences.

[23]  H. Klawans,et al.  Levodopa-induced psychosis: a kindling phenomenon. , 1978, The American journal of psychiatry.

[24]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[25]  D. Jeste,et al.  Psychotic Symptoms in Parkinson's Disease Patients with Dementia , 1996, Journal of the American Geriatrics Society.

[26]  H. Klawans Levodopa-Induced Psychosis , 1978 .

[27]  M. Hutchinson,et al.  Cholinesterase inhibition in Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[28]  M. Kuskowski,et al.  Serum Anticholinergic Activity in Hospitalized Older Persons with Delirium: A Preliminary Study , 1995, Journal of the American Geriatrics Society.

[29]  D. Aarsland,et al.  Patient Characteristics, MRI Examination, and Dopaminergic Drug Response in Clinical Possible Parkinson's Disease , 1996, Journal of geriatric psychiatry and neurology.

[30]  J. Cummings,et al.  Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.

[31]  G. Stebbins,et al.  Risk factors for nursing home placement in advanced Parkinson's disease , 1993, Neurology.